La diabetes mellitus en el contexto de la COVID-19
Palabras clave:
Diabetes, Diabetes Mellitus, Infeción por Coronavirus, SARS-Cov-2Resumen
Introducción: una alta prevalencia de la diabetes mellitus representa un desafío durante la pandemia de la enfermedad por coronavirus 2019 o COVID-19. La diabetes mellitus constituye un importante factor de riesgo de complicaciones en pacientes con COVID-19.
Objetivo: describir las características clínicas, epidemiológicas y moleculares; así como opciones de tratamiento en los pacientes con COVID-19 y diabetes mellitus.
Método: se realizó una revisión bibliográfica en artículos publicados en revistas biomédicas revisadas por pares hasta junio de 2020. Se revisaron las bases de datos SciELO y PubMed. Los términos de búsqueda incluyeron diabetes mellitus, coronavirus infection, y su traducción al español «diabetes mellitus», «infección por coronavirus».
Desarrollo: La COVID-19 y los pacientes diabéticos pueden estar predispuestos a una disfunción inmunológica que resulta en una enfermedad tardía severa. La mayoría de los pacientes con infección leve pueden continuar con los medicamentos anti-hiperglucémicos habituales. El resultado del uso de corticoesteroides aún no está claro. Existen preocupaciones de seguridad con respecto al tratamiento con cloroquina/hidroxicloroquina, en relación con su función hipoglucémica y demás efectos adversos.
Conclusiones: los mecanismos moleculares fisiopatológicos entre la COVID-19 y la diabetes mellitus todavía no están del todo dilucidados. El mal pronóstico que se observa en pacientes con ambas enfermedades requiere la creación de nuevos protocolos de tratamiento.
Descargas
Citas
1. Paules CI, Marston HD, Fauci AS. Coronavirus Infections—More Than Just the Common Cold. JAMA [Internet]. 2020 [Cited 25 June 2020];323(8):707-8. Available from: https://jamanetwork.com/journals/jama/fullarticle/2759815
2. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses and diabetes mellitus. Am J Physiol Endocrinol Metab [Internet]. 2020 Mar [Cited 25 June 2020]; 318(5): [About 6 p.]. Available from: https://journals.physiology.org/doi/pdf/10.1152/ajpendo.00124.2020
3. Katulanda P, Dissanayake HA, Ranathuga I, Ratnasamy V, Wijewickrama PSA, et. al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of literature. Diabetologia [Internet] 2020 May [Cited 25 June 2020]; 63(2020): 1440-1452: [Aprox. 13p.] Disponible desde: https://link.springer.com/article/10.1007/s00125-020-05164-x
4. Infomed. Information note on COVID-19 in Cuba: June 21 [Internet]. Havana: National Center for Information on Medical Sciences. [Actualized June 21, 2020; cited 22 June 2020] Available from: https://temas.sld.cu/coronavirus/2020/06/22/nota-informativa-sobre-la-covid-19-en-cuba-21-de-junio/
5. Bello-Chavolla OY, Bahena-Lopez JP. Predicting mortality due to SARS-Cov-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in México. Jour Clin Endo Meta [Internet]. 2020 May [Cited 25 June 2020]; 105(8) [About 28 p.] Available from: https://academic.oup.com/jcem/article/105/8/dgaa346/5849337
6. Iacobellis G. COVID-19 and Diabetes: can DPP4 inhibition play a rol? Diabetes Res Clin Pract [Internet]. 2020 Mar [Cited 27 Abr 2020]; 162(2020): [About 8 p.]. Available from: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(20)30375-2/fulltext
7. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr [Internet]. 2020 Abr [Cited 25 June 2020]; 14(4): [About 22 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162793/
8. Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev [Internet]. 2020 June [Cited 25 Jun 2020]; 41(3): [About 28 p.]. Available from: http://samin.es/wp-content/uploads/2020/04/bnaa011.pdf
9. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev [Internet]. 2020 April [Cited 25 June 2020]; 7(e3319): [About 9 p.]. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/dmrr.3319
10. Kumar Singh A, Gupta R, Gosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. [Internet]. 2020 April. [Cited 25 June 2020]; 14(4): [About 7 p.]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1871402120300631
11. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diab Met Res Rev. [Interntet]. 2020 July. [Cited 25 June 2020]; 14(4) [About 15 p.]. Available form: doi: https://www.sciencedirect.com/science/article/pii/S1871402120301144
12. Hussin A, Rothan E, Siddappa N, Byrareddy T. The epidemiology and pathogenesis of coronavirus disease (COVID-19). Outbreak Journal of Autoimmunity [Internet]. 2020 [Cited 25 June 2020]; 102(433): [About 1 p.]. Available from: https://www.sciencedirect.com/science/article/pii/S0896841120300469
13. Rodriguez-Morales A. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious Disease [Internet]. 2020 Mar [Cited 25 June 2020]; 30(40): [About 2 p.]. Available from: https://www.sciencedirect.com/science/article/pii/S1477893920300910
14. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diab Met Res Rev [Internet]. 2020 May-June [Cited 25 Abr 2020]; 14(3): [About 7 p.]. Available from: https://www.sciencedirect.com/science/article/pii/S1871402120300515
15. Bornstein SR, Rubino F, Khunti K. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diab Endocrinol [Internet]. 2020 April [Cited 25 June 2020]; 8(546-50): [About 4 p.]. Available from: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30152-2/fulltext
16. Bornstein SR, Delan R, Hopkins D, Mingrone G, Boehm BO. El vínculo endocrino y metabólico de COVID-19. Nat Rev Endocrinol [Internet]. 2020 June [Cited 25 June 2020]; 16(297-298): [About 10 p.] Available from: https://www.nature.com/articles/s41574-020-0353-9
17. Guandi L, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCov). Nature Reviews Drug Discovery [Internet]. 2020 [Cited 25 June 2020]; 19:149-50: [About 2 p.]. Available from: https://media.nature.com/original/magazine-assets/d41573-020-00016-0/d41573-020-00016-0.pdf
18. Gupta R, Hussain A, Misra A. Diabetes and COVID-19: evidence, current status and unanswered research questions. Eur J Clin Nutr. [Internet]. 2020 May. [Cited 25 June 2020]; 74(864-870): [Aprox. 7 p]. Available from: https://www.nature.com/articles/s41430-020-0652-1
19. Stoian AP, Banerjee Y, Rizvi AA, Rizzo M. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. Metab Syndr Relat Disord [Internet]. 2020 [Cited 25 June 2020]; 18(4): [About 4 p.]. Available from: https://www.liebertpub.com/doi/full/10.1089/met.2020.0037
20. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract [Internet]. 2020 May [Cited 25 June 2020]; 163(108146): [About 5 p.]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151403/
